Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

he improvements were achieved without any limiting next day cognitive effects. In both the Phase 1 program and the Phase 2a trial, APD125 was well tolerated at all doses investigated.

About APD125

Discovered by Arena, APD125 is a novel and oral selective inverse agonist of the 5-HT2A serotonin receptor. The vast majority of approved drugs for insomnia activate the GABA-A receptor complex in the brain, causing a general suppressive effect on the central nervous system, or CNS. These GABAergic drugs are generally associated with CNS side effects, including a sensation of dullness and lethargy upon awakening, often referred to as the "hangover effect." Other potential problems associated with the GABAergic drugs include the risk of developing tolerance and drug dependency in at-risk populations. In addition, GABAergic drugs are scheduled controlled substances by the Drug Enforcement Administration due to their potential for abuse.

By selectively targeting the 5-HT2A receptor, APD125 acts through a different mechanism than currently marketed insomnia drugs and blocks one of several CNS activating pathways. Because of the different mechanism of action, APD125 may not have the side effects or abuse potential generally associated with currently approved GABAergic drugs. Through its novel mechanism, APD125 has the potential to reduce insomnia symptoms by improving sleep maintenance.

About Insomnia

Insomnia is characterized by inadequate or poor sleep due to nonrefreshing sleep, frequent wakening with difficulty falling back to sleep, difficulty falling asleep or waking too early. Most insomnia complaints relate to sleep maintenance issues, such as waking frequently or awakening too early, as opposed to problems with sleep latency (i.e. falling asleep). About 30% of US adults report some level of insomnia in the course of a year, and about 10% of US adults indicate that their condition is chronic. In these cases, the lack of restful sleep i
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 Research and ... "Biopharmaceutical and Vaccine Production Markets" report to their ... new therapies and vaccines - including products to treat ... still huge challenges during the final stages of clinical ... and how to risk production capital to upscale while ...
(Date:9/23/2014)... 23, 2014  SiteOne Therapeutics Inc. today announced the ... by Sears Capital Management and Biobrit LLC, with additional ... the $1.5 million financing positions SiteOne to advance its ... to further develop its technology platform for long-acting local ... In conjunction with the financing, Lowell Sears ...
(Date:9/23/2014)...   COTA, Inc. today announced it has ... A funding round led by Horizon Healthcare Services, Inc. ... big data platform designed by practicing oncologists to deliver ... care in support of healthcare,s new value-based reimbursement model. ... of the COTA platform, hire biostatisticians, outcome analysts, data ...
Breaking Medicine Technology:Biopharmaceutical and Vaccine Production Markets 2Biopharmaceutical and Vaccine Production Markets 3SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
(Date:9/23/2014)... 2014 (HealthDay News) -- The U.S. National Institutes ... funding in scientific trials to encourage researchers to ... The supplemental monies were provided to 82 ... immunology, cardiovascular physiology, neural circuitry, and behavioral health, ... "This funding strategy demonstrates our commitment to moving ...
(Date:9/23/2014)... Center have published the first study to extensively ... The Journal of Allergy and Clinical Immunology ... that has high levels of eosinophils in the ... allergy-associated-immune mechanisms and has a gene expression pattern ... related disorder, eosinophilic esophagitis (EoE). , Eosinophilic ...
(Date:9/23/2014)... 23, 2014) Laparoscopic cholecystectomy, a minimally invasive procedure to ... abdominal surgeries in the U.S. Yet medical centers around ... with some moving patients quickly into surgery while others ... the American Journal of Surgery , researchers found ... rather than rushing the patients into the operating room ...
(Date:9/23/2014)... Act "Obamacare" was signed into law in ... healthcare system since the 1960s. Designed to provide medical ... as an unwarranted intrusion into the affairs of private ... of healthcare systems in six Western countries, published last ... a move away from privatized medicine toward state-sponsored healthcare ...
(Date:9/23/2014)... 2014 Royal Sport Ultra Clean 100 ... LTD family of premium sports nutrition products. Its gluten ... Whey protein without artificial colors or dyes, fillers, added ... available on shelves at select GNC retailers, on GNC.com, ... is offering a limited time special on its products. ...
Breaking Medicine News(10 mins):Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:Advancing the understanding of an understudied food allergy disorder 2Health News:Advancing the understanding of an understudied food allergy disorder 3Health News:Study finds gallbladder surgery can wait 2Health News:Life, liberty, and the pursuit of healthcare? 2Health News:Sports Nutrition Brand, Royal Sport LTD, Introduces 'Clean,' Gluten Free Protein Supplement, Royal Sport Ultra Clean 100™ 2
... intensive therapy works well, study finds , THURSDAY, Aug. ... (RA) who respond poorly to standard treatment with methotrexate ... (TNF) blockers, a Swedish study suggests. , Previous research ... patients have a good response to methotrexate therapy and ...
... , , MISSION VIEJO, Calif., ... the parent company of the Ensign(TM) group of skilled nursing, rehabilitative care ... quarter of fiscal year 2009. , , (Logo: ... Include: , , Total revenue was ...
... , , RANCHO CORDOVA, Calif., ... ), a leading supplier of innovative products for processing and storing ... BMC ("Res-Q") System, an automated cell processing medical device for the ... , , The Res-Q System processes bone ...
... American Health Assistance Foundation Researcher Is Featured Facilitator , ... Health Assistance Foundation and Asbury Methodist Village are partnering to host a ... Project to bring awareness to the community about this devastating disease, ... Part one of the Momentum in Science ...
... ... The Angelman Syndrome Foundation, www.angelman.org , announced the ... direct the organization,s rapidly increasing research funding. The ATRI will also ... scientists worldwide to share discoveries and treatments for this neuro-genetic disorder. ...
... BETHESDA, Md., Aug. 6 /PRNewswire-Asia/ -- , ... CHDX ), a leading,independent American provider ... Republic of China, today announced that the Company,s,Western-style ... a comprehensive, international-standard oncology program, called "New,Hope," at ...
Cached Medicine News:Health News:TNF Blockers May Help Some With Rheumatoid Arthritis 2Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 2Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 3Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 4Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 5Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 6Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 7Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 8Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 9Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 10Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 11Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 12Health News:The Ensign Group Reports Second Quarter 2009 Earnings of $0.39 per Share; Reaffirms 2009 EPS Guidance 13Health News:ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector 2Health News:ThermoGenesis Announces Launch of Res-Q System; New Device Expands Company's Presence in Bone Marrow Sector 3Health News:American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screening and Discussion of the HBO Series, The Alzheimer's Project 2Health News:American Health Assistance Foundation & Asbury Methodist Village to Host Special Community Screening and Discussion of the HBO Series, The Alzheimer's Project 3Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 2Health News:Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 4
A system with integrated pupil camera and 7" examination monitor. An easy to use configuration....
... Laserex Tango ophthalmic laser system provides two ... laser and a photodisruptor for posterior capsulotomy ... frequency-doubled Nd:YAG producing pulsed 532 nm light. ... 1064 nm. The appropriate laser can be ...
Extremely thin and smooth jaws, jaws open to 5.5 mm, cross action....
Flat handle cross action....
Medicine Products: